SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
Open accessThe DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular (CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of antidiabetic medication that inhibit the absorption of glucose from the proximal tubule of the kidney and hence cause glycosuria. Four SGLT2i are currently commercially available in many countries: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin. SGLT2i reduce glycated hemoglobin by 0.5%–1.0% and have shown favorable effects on body weight, blood pressure, lipid profile, arterial stiffness and endothelial function. More importantly, SGLT2i have demonstrated impressive cardioprotective and renoprotective effects. The main mechanisms underlying their cardioprotective effects have been attributed to improvement in cardiac cell metabolism, improvement in ventricular loading conditions, inhibition of the Na+/H+ exchange in the myocardial cells, alteration in adipokines and cytokines production, as well as reduction of cardiac cells necrosis and cardiac fibrosis. The main adverse events of SGLT2i include urinary tract and genital infections, as well as euglycemic diabetic ketoacidosis. Concerns have also been raised about the association of SGLT2i with lower limb amputations, Fournier gangrene, risk of bone fractures, female breast cancer, male bladder cancer, orthostatic hypotension, and acute kidney injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT2-i improves the metabolic profile in patients with diabetes increasing glycosuria by inhibiting glucose reuptake in the renal proximal tubule. As a result, they induce a reduction of both arterial pressure and body weight, demonstrating impressive cardio- and nephro-protective effects [59].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 10×
“The EMPA-REG OUTCOME trial and the CANVAS program showed that the administration of Empa or Cana increased both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) when compared with placebo [65,68].”
BackgroundMethodResultInfluentialAhmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663 · cited 5×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundInfluentialOLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 14×
“Nevertheless, it is unlikely that the latter can fully explain the impressive effect of SGLT2i on renal outcomes since patients in these studies were treated with RAASi [87].”
BackgroundMethodResultInfluential10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382 · cited 10×
“Results of DECLARE-TIMI, nevertheless, did not confirm a higher cancer risk with Dapa [69].”
BackgroundMethodResultInfluentialCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“Administration of Cana led to the reduction of end-stage renal disease, doubling of the serum creatinine level, or death from renal or CV causes [85].”
Background
Cited by
Items 301–325 of 325
Batista, S. J., Luz, M. D. S., Leão, D. S. C., Paiva, O. R., Maslinkiewicz, A., Ferreira, F. C., Santos, W. L., Datsch, M. R., Benítez, F. J. G., Parra, J. A. M., et al. (2026) · DELOS Desarrollo Local Sostenible · doi:10.55905/rdelosv19.n76-064
Yu, S., Li, J., Wu, X., Lu, S., Li, C., Cheng, H., Guo, H., Yang, P., & Wang, L. (2026) · Medicine · doi:10.1097/md.0000000000047306
“[6] However, recent studies have shown that SGLT2is not only have an important role in diabetes treat-ment but also reduce the incidence of adverse cardiovascular events and delay the progression of CHD. [7] Terasaki et al have demonstrated that SGLT2i–dapagliflozin–can prevent atherosclerosis by…”
Kuoni, S., Dolder, A., Lehmann, R., Steiner, R., Ochsenbein-Kölble, N., & Simões‐Wüst, A. P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119097 · Cited by 1
Visram, A. (2021) · TSpace (University of Toronto)
Microbial metabolites as promising alternatives to empagliflozin for type 2 diabetes management
Rakib, A. R., Bristy, T. A., Shifa, J., Surovi, S., Banik, M., Bushra, A., Sultana, T., Joyoti, S. A., Mahmud, M. T., Ahmed, F., et al. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00779-3
Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes
Chuan, F., Gao, Y., & Zhou, B. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2600572
Candida albicans urinary tract infection in a cat treated with velagliflozin
Clanxet, J., Feo, L., & Puig, J. (2026) · Journal of Feline Medicine and Surgery Open Reports · doi:10.1177/20551169261445535
Lu, X., Xu, J., Liu, S., & Chen, S. (2026) · Cardiology Discovery · doi:10.1097/cd9.0000000000000193
Pharmacological and Nanotechnological Insights into SGLT-2 Inhibitors for Type 2 Diabetes Management
Singh, S., Grewal, S., Sharma, N., Kishore, L., Kumar, P., Verma, S., & Gupta, S. (2026) · Letters in Applied NanoBioScience · doi:10.33263/lianbs151.025
Hegazy, M. K., Masoud, R., Othman, B., & Alhusseiny, S. M. (2026) · Scientific Reports · doi:10.1038/s41598-026-55860-8
Салухов, В. В., Puzhalov, I. A., Santakov, A. A., & Varavin, N. A. (2025) · Медицинский вестник МВД · doi:10.52341/20738080_2025_139_6_36
Yaşlanma Kader mi? Yaşlanma Biyolojisi ve Genetiği
Lüleyap, H. Ü. (2026) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.4073
Mohammadi, D., Sadeghirad, B., Rasouli, M. A., Saed, L., Baradaran, H. R., & Moradi, Y. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02226-9
“More recently, glucagon-like peptide-1 receptor agonists (GLP-1) and sodium‒glucose cotransporter-2 (SGLT2) inhibitors have been shown to significantly reduce both primary and secondary cardio-vascular events, particularly in high-risk patients [18, 19].”
Yen, T., Lu, C. A., Hsieh, T. Y. J., Lee, G. Y., Jiang, C., & Tanner, E. J. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.06.023
Patel, P., Patel, X., Patel, Z., Prajapati, A., & Patel, S. (2026) · Pharmaceutical and Biomedical Research · doi:10.32598/pbr.12.2.1450.1
Minden, A. (2026) · Springer eBooks · doi:10.1007/978-3-032-20529-2_13
Meyer, M. S., Ramesh, S., Rammouni, Y., Lasry, S., Sawan, H., & Zakaria, K. (2026) · Cureus · doi:10.7759/cureus.114227
3159 Cross-coupling reactions: A powerful tool in carbohydrate chemistry
Gupta, S., & Gauthier, C. (2026) · De Gruyter eBooks · doi:10.1515/9783111739601-010
Sun, X., Wang, L., Li, G., Zhang, H., Li, L., Xiang, G., Wang, T., Dong, L., Chen, J., & Wang, A. (2026) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000002144
Manunta, M., Bruno, G. M., Ferrantelli, A., Ramirez, R. F., & Nardi, F. (2026) · Drugs in Context · doi:10.7573/dic.2026-8-5
RASHID1, S. A., Selva, P., & YASHVANTHAN, V. R. (2025) · TPM Testing, psychometrics, methodology in applied psychology
Romero, M. A. C., & Bravo, A. C. O. (2023) · Polo del Conocimiento · doi:10.23857/pc.v8i6.5686
Kajo, C., AlAraibi, A. J., Almutairi, O. T., Alaraibi, Y. H., Alibrahim, A. A., Almutawah, Y. K. A., Alasfar, S. W. S., Ali, M. W., Hajjiri, A., Alqaryuti, M., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1976876
Mechanistic insights into lactate-driven pathogenesis in diabetic kidney disease
He, S., Yang, L., & Yin, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1950569
“SGLT2i are a new generation of glucose-lowering agents that reduce glucose reabsorption in the renal proximal tubule, playing a significant role in glycemic control and cardiovascular disease prevention (Tentolouris et al., 2019).”
Metadata
- Authors
- Tentolouris, A., Vlachakis, P., Tzeravini, E., Eleftheriadou, I., & Tentolouris, N.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, 11527 Athens, Greece
- Venue
- International Journal of Environmental Research and Public Health
- Publisher
- MDPI AG
- Published
- 2019-08-17
- Volume
- 16
- Issue
- 16
- Pages
- 2965
- ISSN
- 1660-4601 (ISSN-L)
- PMC
- PMC6720282
- OpenAlex
- W2967960051
- Cited by
- 300
- References
- 183
- Citations by year
- 2026: 25 · 2025: 43 · 2024: 55 · 2023: 54 · 2022: 54 · 2021: 40 · 2020: 26 · 2019: 2
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Environmental Research and Public Health (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- SGLT2 inhibitors, type 2 diabetes, cardioprotection, renal protection, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, glycosuria, HbA1c, arterial stiffness, endothelial function, Na+/H+ exchange, myocardial fibrosis, adverse events, lower limb amputation, acute kidney injury, cardiovascular risk
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Cardiotonic Agents, Cardiovascular System, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.